APVO101 — Competitive Intelligence Brief

APVO101 (APVO101) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual checkpoint inhibitor. Area: Oncology.

phase 3 Dual checkpoint inhibitor PD-1 and CTLA-4 Oncology Small molecule

Target snapshot

APVO101 (APVO101) — Medexus Pharma, Inc.. APVO101 is a dual checkpoint inhibitor that blocks both PD-1 and CTLA-4 pathways to enhance anti-tumor immune responses.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
APVO101 TARGET	APVO101	Medexus Pharma, Inc.	phase 3	Dual checkpoint inhibitor	PD-1 and CTLA-4
Nivolumab in combination with Ipilimumab	Nivolumab in combination with Ipilimumab	Bristol-Myers Squibb	marketed	Checkpoint inhibitor combination (PD-1 inhibitor + CTLA-4 inhibitor)	PD-1 and CTLA-4
Adjuvant Nivolumab and Ipilimumab	Adjuvant Nivolumab and Ipilimumab	Universitätsklinikum Hamburg-Eppendorf	phase 3	PD-1 inhibitor and CTLA-4 inhibitor combination	PD-1 and CTLA-4
Neoadjuvant ipilimumab + nivolumab	Neoadjuvant ipilimumab + nivolumab	The Netherlands Cancer Institute	phase 3	Immune checkpoint inhibitor combination	PD-1 and CTLA-4
Nivolumab & Ipilimumab	Nivolumab & Ipilimumab	The First Affiliated Hospital of Guangzhou Medical University	phase 3	PD-1 inhibitor + CTLA-4 inhibitor combination	PD-1 and CTLA-4
AK102	AK102	Akeso	phase 3	Bispecific checkpoint inhibitor	PD-1 and CTLA-4
Nivolumab + Relatlimab	Nivolumab + Relatlimab	H. Lee Moffitt Cancer Center and Research Institute	marketed	Dual checkpoint inhibitor (PD-1 and LAG-3 inhibitor combination)	PD-1 and LAG-3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual checkpoint inhibitor class)

1. Medexus Pharma, Inc. · 1 drug in this class